Literature DB >> 26957555

Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors.

Eneda Toska1, José Baselga2.   

Abstract

The PI3K pathway is often aberrantly activated in estrogen receptor positive (ER(+)) breast cancer and therapies combining PI3K inhibitors and antiestrogens are under clinical development. Given that many PI3K inhibitors have substantial toxicities with continuous dosing and that alternate dosing schedules are equally active, further clinical exploration is warranted. Clin Cancer Res; 22(9); 2099-101. ©2016 AACRSee related article by Yang et al., p. 2250. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26957555      PMCID： PMC4946572          DOI： 10.1158/1078-0432.CCR-16-0038

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  7 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

2.  Tumor size, sensitivity to therapy, and design of treatment schedules.

Authors:  L Norton; R Simon
Journal:  Cancer Treat Rep       Date:  1977-10

3.  Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.

Authors:  H K Chew; G Somlo; P C Mack; B Gitlitz; R Gandour-Edwards; S Christensen; H Linden; L J Solis; X Yang; A M Davies
Journal:  Ann Oncol       Date:  2011-07-21       Impact factor: 32.976

4.  Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Authors:  Omar Abdel-Wahab; Virginia M Klimek; Alisa A Gaskell; Agnes Viale; Donavan Cheng; Eunhee Kim; Raajit Rampal; Mark Bluth; James J Harding; Margaret K Callahan; Taha Merghoub; Michael F Berger; David B Solit; Neal Rosen; Ross L Levine; Paul B Chapman
Journal:  Cancer Discov       Date:  2014-03-03       Impact factor: 39.397

5.  Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.

Authors:  Wei Yang; Sarah R Hosford; Lloye M Dillon; Kevin Shee; Stephanie C Liu; Jennifer R Bean; Laurent Salphati; Jodie Pang; Xiaolin Zhang; Michelle A Nannini; Eugene Demidenko; Darcy Bates; Lionel D Lewis; Jonathan D Marotti; Alan R Eastman; Todd W Miller
Journal:  Clin Cancer Res       Date:  2016-01-05       Impact factor: 12.531

6.  Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.

Authors:  Neil P Shah; Corynn Kasap; Christopher Weier; Minna Balbas; John M Nicoll; Eric Bleickardt; Claude Nicaise; Charles L Sawyers
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

7.  First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

Authors:  Debashis Sarker; Joo Ern Ang; Richard Baird; Rebecca Kristeleit; Krunal Shah; Victor Moreno; Paul A Clarke; Florence I Raynaud; Gallia Levy; Joseph A Ware; Kathryn Mazina; Ray Lin; Jenny Wu; Jill Fredrickson; Jill M Spoerke; Mark R Lackner; Yibing Yan; Lori S Friedman; Stan B Kaye; Mika K Derynck; Paul Workman; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2014-11-04       Impact factor: 12.531
  7 in total
  9 in total

Review 1.  Effective implementation of novel MET pharmacodynamic assays in translational studies.

Authors:  Apurva K Srivastava; Tony Navas; William G Herrick; Melinda G Hollingshead; Donald P Bottaro; James H Doroshow; Ralph E Parchment
Journal:  Ann Transl Med       Date:  2017-01

Review 2.  PI3K Inhibitors in Breast Cancer Therapy.

Authors:  Haley Ellis; Cynthia X Ma
Journal:  Curr Oncol Rep       Date:  2019-12-11       Impact factor: 5.075

3.  Quantitative systems pharmacology model-based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3-kinase inhibitors.

Authors:  Kapil Gadkar; Christina Friedrich; Vincent Hurez; Maria-Luisa Ruiz; Leslie Dickmann; Mohit Kumar Jolly; Leah Schutt; Jin Jin; Joseph A Ware; Saroja Ramanujan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-12-13

4.  Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade.

Authors:  Hui-Wen Lue; Jennifer Podolak; Kevin Kolahi; Larry Cheng; Soumya Rao; Devin Garg; Chang-Hui Xue; Juha K Rantala; Jeffrey W Tyner; Kent L Thornburg; Ann Martinez-Acevedo; Jen-Jane Liu; Christopher L Amling; Charles Truillet; Sharon M Louie; Kimberly E Anderson; Michael J Evans; Valerie B O'Donnell; Daniel K Nomura; Justin M Drake; Anna Ritz; George V Thomas
Journal:  Genes Dev       Date:  2017-11-14       Impact factor: 11.361

5.  The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.

Authors:  Hanjiao Qin; Linlin Liu; Shu Sun; Dan Zhang; Jiyao Sheng; Bingjin Li; Wei Yang
Journal:  PeerJ       Date:  2018-06-19       Impact factor: 2.984

Review 6.  The PTEN⁻PI3K Axis in Cancer.

Authors:  Antonella Papa; Pier Paolo Pandolfi
Journal:  Biomolecules       Date:  2019-04-17

Review 7.  Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.

Authors:  Klaus Okkenhaug; Mariona Graupera; Bart Vanhaesebroeck
Journal:  Cancer Discov       Date:  2016-09-21       Impact factor: 39.397

8.  First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Authors:  A Patnaik; L J Appleman; A W Tolcher; K P Papadopoulos; M Beeram; D W Rasco; G J Weiss; J C Sachdev; M Chadha; M Fulk; S Ejadi; J M Mountz; M T Lotze; F G S Toledo; E Chu; M Jeffers; C Peña; C Xia; S Reif; I Genvresse; R K Ramanathan
Journal:  Ann Oncol       Date:  2016-10       Impact factor: 32.976

9.  The present and future of PI3K inhibitors for cancer therapy.

Authors:  Pau Castel; Eneda Toska; Jeffrey A Engelman; Maurizio Scaltriti
Journal:  Nat Cancer       Date:  2021-06-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.